Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 480-486

  Warlick, Erica D ^a   DeFor, Todd ^a   Blazar, Bruce R ^a   Burns, Linda ^a   Verneris, Michael R ^a   Ustun, Celalettin ^a   Weisdorf, Daniel J ^a   Miller, Jeffrey S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

Author keywords

Allogeneic cell transplantation; DLI; Donor lymphocyte infusion; Lymphodepleting chemotherapy; Relapse

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DONOR LYMPHOCYTE INFUSION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DYSFUNCTION; MALE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; OVERALL SURVIVAL; RASH; SKIN MALFORMATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; RECURRENCE; REMISSION, SPONTANEOUS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84862828192     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.030     Document Type: Article

References (18)

1. Pavletic S.Z., Kumar S., Mohty M., et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following allogeneic cell transplantation. Biol Blood Marrow Transplant 2010, 16:871-890.
2. Bishop M.R., Dean R.M., Steinberg S.M., et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008, 19:1935-1940.
3. Bloor A.J., Thomson K., Chowdhry N., et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008, 14:50-58.
4. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
5. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002, 20:405-412.
6. Deol A., Lum L.G. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010, 36:528-538.
7. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
8. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
9. Shiobara S., Nakao S., Ueda M., et al. Donor leukocyte infusionfor Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome. Bone Marrow Transplant 2000, 26:769-774.
10. Choi S.J., Lee J.H., Lee J.H., et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004, 18:1789-1797.
11. Inamoto Y., Fefer A., Sandmaier B.M., et al. A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1308-1315.
12. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.
13. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-2357.
14. Miller J.S., Weisdorf D.J., Burns L.J., et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007, 110:2761-2763.
15. Snedecor G., Cochran W. Statistical Methods 1989, Iowa State University Press, Ames, IA. 8th ed.
16. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risk studies. Stat Med 1997, 16:901-910.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1995, 53:457-481.
18. Wrzesinski C., Paulos C.M., Kaiser A., et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 2010, 33:1-7.